Study: The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

October 19, 2022 The current evidence suggests CBD at doses of 300–400 mg has promise, especially as an anxiolytic and anti-addiction agent, and larger randomized, double-blind, placebo-controlled trials are required to reinforce these data.